GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Nucala Becomes First Biologic Approved for COPD with Eosinophilic Inflammation The FDA’s approval of GSK’s Nucala (mepolizumab) introduces the first biologic treatment for patients with chronic ...

Nucala, which is administered as a once-monthly subcutaneous injection, won its first FDA approval in 2015 as a treatment for severe asthma. The Thursday approval came later than GSK expected.

On GSK's media call earlier this month, Miels noted that the company plans to “essentially keep the same pricing structure that we already have” with Nucala, which currently costs around ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review its application to expand the use of Nucala (mepolizumab), a monoclonal antibody that targets ...

GSK said that if approved, Nucala could be the first biologic with monthly dosing for patients with COPD, which affects more than 390 million people globally and over 40 million people in Europe.

GSK plc (LSE/NYSE: LON: GSK), a prominent pharmaceutical company with a market capitalization of $73 billion and impressive gross margins of 72%, announced today that the China National Medical (TASE: ...

Nucala is currently approved for use in China across three interleukin-5 mediated conditions. IL-5 is a key cytokine in type 2 inflammation which is an underlying driver in many diseases, GSK said.

In other recent news, GlaxoSmithKline (NYSE: GSK) reported its fourth-quarter revenue, which surpassed analyst estimates, reaching £8.12 billion.